Nexium

2 Risks Facing Merck Today

2 Risks Facing Merck Today

Motley Fool

3rd Circuit pay-for-delay ruling sparks Nexium antitrust suits

3rd Circuit pay-for-delay ruling sparks Nexium antitrust suits

Reuters

Pfizer-AstraZeneca’s Nexium Deal. Win-Win for both Companies?

Pfizer-AstraZeneca’s Nexium Deal. Win-Win for both Companies?

Motley Fool

Pfizer paying AstraZeneca $250M for rights to nonprescription version of heartburn drug Nexium

Pfizer paying AstraZeneca $250M for rights to nonprescription version of heartburn drug Nexium

Yahoo/AP

Merck to keep recording income from Astra drugs

Merck to keep recording income from Astra drugs

Reuters

FDA says ulcer drugs may raise diarrhea risk

FDA says ulcer drugs may raise diarrhea risk

Reuters

Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrifices

Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrifices

Fierce Pharma

Lipitor's $131B lifetime sales dwarf other megablockbusters

Lipitor's $131B lifetime sales dwarf other megablockbusters

Fierce Pharma

AstraZeneca Rep Is Sued By Nexium Patients

AstraZeneca Rep Is Sued By Nexium Patients

Pharmalot

Medco, Astra get U.S. subpoenas over four drugs

Medco, Astra get U.S. subpoenas over four drugs

Reuters